(Q35224171)

7 August 2017

0 references

Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis (English)

1 reference

7 August 2017

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119841%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Fausto Pinto

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119841%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Márcio Barra

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119841%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Joaquim J Ferreira

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119841%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

João Costa

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119841%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

publication date

14 August 2014

1 reference

7 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119841%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

262

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119841%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119841%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

516-522

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119841%20AND%20SRC:MED&resulttype=core&format=json

Novel oral anticoagulants: clinical pharmacology, indications and practical considerations

3 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Death and disability from warfarin-associated intracranial and extracranial hemorrhages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Meta-analysis of rivaroxaban and bleeding risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Meta-analysis of incidence of rare events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Small studies may overestimate the effect sizes in critical care meta-analyses: a meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Comparison of two methods to detect publication bias in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Apixaban or enoxaparin for thromboprophylaxis after knee replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Apixaban with antiplatelet therapy after acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Apixaban in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Apixaban versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Oral apixaban for the treatment of acute venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Extended use of dabigatran, warfarin, or placebo in venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Edoxaban versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Rivaroxaban in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Rivaroxaban for thromboprophylaxis in acutely ill medical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Risk of primary intracerebral haemorrhage associated with aspirin and non-steroidal anti-inflammatory drugs: case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Intracranial and fatal bleeding according to indication for long-term oral anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7462-0

Apixaban for extended treatment of venous thromboembolism

21 January 2018

1 reference

12 December 2020

Clinically useful measures of the effects of treatment

1 reference

12 December 2020

Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –

1 reference

12 December 2020

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

1 reference

12 December 2020

10.1007/S00415-014-7462-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119841%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1 reference